Summary:
When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.
More specifically:
- Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplication
- Designing trials around real patients rather than ideal patients
- Better understanding the objectives of the study and asking the questions that achieve those objectives
- Better partnering with patients and PIs
To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.
Moderators
Steve Zelenkofske, DO
President/Principal
SLZ Consulting
Panelists
Judith Ng-Cashin, MD
Chief Medical Officer
Novotech
Christopher Morabito, MD
CMO
Astria Therapeutics
Bertil Lindmark, MD, PhD
CMO
Vicore Pharma
Erik Scalfaro
CEO & Founder
Rivia
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.